A rare case of sudden blindness following mepolizumab withdrawal in EGPA

The permanent blindness observed in our patient may be associated with Mepolizumab withdrawal. Currently, there is limited clinical evidence regarding the effects of biologic therapy discontinuation, even in patients with stable diseases. To our knowledge, this is the first reported case of EGPA-associated blindness following Mepolizumab withdrawal. Our case underscores the need for long-term monitoring and careful risk assessment before considering treatment discontinuation, even in the absence of active symptoms.